


Ultra-Low Dose Buprenorphine to Sustain Antidepressant and Antisuicidal Effects of Intravenous Ketamine in Treatment-Resistant Depression with Suicidal Ideation: Protocol Design and Preliminary Results from a Randomized Controlled Trial


Authors: Igor D. Bandeira¹, Jason Tucciarone¹, Ian H. Kratter¹, Jarrod Ehrie¹, Audrey G. Evers¹, Heather Pankow¹, Jessica Hawkins¹, Maureen Chang¹, Jennifer Keller¹, Boris D. Heifets¹, Charles DeBattista¹, Alan F. Schatzberg¹

1. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, United States

■ Introduction:




Ketamine



Buprenorphine

Methods:



Results:

Baseline characteristics	n=48
Age, M (SD)	37.58 (11.23)
Sex, n (%)	
Female	33 (68.75)
Race, n (%)	
White	34 (72.34)
Ethnicity, n (%)	
Hispanic or Latino	9 (18.75)

Clinical scale	Day 1, M (SD)	Day 3, M (SD)	P-value	Response (%)	Remission (%)
MADRS	34.12 (4.74)	21.06 (11.52)	<.0001	37.5	25
BSSI	15.1 (4.03)	7.12 (6.25)	<.0001	54.17	NA